Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1977 1
1978 1
1980 1
1982 3
1983 1
1984 4
1985 5
1986 6
1987 8
1988 16
1989 4
1990 3
1991 1
1992 5
1993 5
1994 6
1995 5
1996 1
1997 1
1998 1
1999 8
2000 9
2001 10
2002 11
2003 17
2004 11
2005 16
2006 11
2007 23
2008 17
2009 16
2010 24
2011 13
2012 12
2013 27
2014 42
2015 49
2016 49
2017 66
2018 84
2019 89
2020 115
2021 122
2022 116
2023 116
2024 140
2025 61

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,178 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: sedghahrabi
Page 1
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Mult Scler Relat Disord. 2024 Jul;87:105594. doi: 10.1016/j.msard.2024.105594. Epub 2024 Apr 6. Mult Scler Relat Disord. 2024. PMID: 38718748 Free article.
Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NEDA-3 achievement in treatment-naive HAMS patients receiving NAT or OCR over three years. ...After three years, the Kaplan-Meier probabili …
Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NED …
A brief history of NEDA.
Giovannoni G, Bermel R, Phillips T, Rudick R. Giovannoni G, et al. Mult Scler Relat Disord. 2018 Feb;20:228-230. doi: 10.1016/j.msard.2017.07.011. Epub 2017 Jul 13. Mult Scler Relat Disord. 2018. PMID: 29579628 No abstract available.
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.
Rotstein D, Solomon JM, Sormani MP, Montalban X, Ye XY, Dababneh D, Muccilli A, Saab G, Shah P. Rotstein D, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Oct 12;9(6):e200032. doi: 10.1212/NXI.0000000000200032. Print 2022 Nov. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36224046 Free PMC article.
However, the ability of NEDA-4 to discriminate long-term outcomes in MS and how its performance compares with NEDA-3 remain uncertain. ...We conducted a meta-analysis using random-effects model to determine the pooled odds ratio (OR) for no disability progression wi …
However, the ability of NEDA-4 to discriminate long-term outcomes in MS and how its performance compares with NEDA-3 remain un …
Are we in need of NEDA?
Freedman MS. Freedman MS. Mult Scler. 2016 Jan;22(1):5-6. doi: 10.1177/1352458515617249. Epub 2015 Nov 9. Mult Scler. 2016. PMID: 26552731 No abstract available.
No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J. Newsome SD, et al. Neurol Ther. 2023 Dec;12(6):1909-1935. doi: 10.1007/s40120-023-00549-7. Epub 2023 Oct 11. Neurol Ther. 2023. PMID: 37819598 Free PMC article. Review.
We identify current challenges to the use of NEDA in clinical practice and detail the proposed amendments, such as the inclusion of alternative outcomes and biomarkers, to broaden the clinical information captured by NEDA. ...One such outcome is the set of criteria …
We identify current challenges to the use of NEDA in clinical practice and detail the proposed amendments, such as the inclusion of a …
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Front Immunol. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676. eCollection 2024. Front Immunol. 2024. PMID: 39606235 Free PMC article.

RESULTS: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) because of INFL and 10 (8.7%) because of PIRA. ...After a year, NEDA-3 and INFL patients showed similar decreases in sNfL (p < 0.000

…
RESULTS: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) be …
The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials.
Wu C, Guo H, Xu Y, Li L, Li X, Tang C, Chen D, Zhu M. Wu C, et al. Front Aging Neurosci. 2022 Apr 22;14:831884. doi: 10.3389/fnagi.2022.831884. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35527736 Free PMC article.

PD patients treated with NEDA or NEDA+open LD had a lower risk of wearing-off implications than those treated with LD (all p < 0.05). ...CONCLUSION: NEDA therapy reduces motor symptoms and improves ADLs in early PD. The odds of developing motor complicatio

…
PD patients treated with NEDA or NEDA+open LD had a lower risk of wearing-off implications than those treated with LD (all p & …
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Sormani MP, Muraro PA, Saccardi R, Mancardi G. Sormani MP, et al. Mult Scler. 2017 Feb;23(2):201-204. doi: 10.1177/1352458516645670. Epub 2016 Jul 11. Mult Scler. 2017. PMID: 27207454 Review.
Achievement of NEDA status in patients receiving a disease-modifying therapy (DMT) seems to be an ambitious but ideal goal for therapies in RRMS. Recently, published post hoc analyses of clinical trials reported percentages of RRMS patients maintaining the NEDA stat …
Achievement of NEDA status in patients receiving a disease-modifying therapy (DMT) seems to be an ambitious but ideal goal for therap …
NEDA treatment target? No evident disease activity as an actionable outcome in practice.
Parks NE, Flanagan EP, Lucchinetti CF, Wingerchuk DM. Parks NE, et al. J Neurol Sci. 2017 Dec 15;383:31-34. doi: 10.1016/j.jns.2017.10.015. Epub 2017 Oct 13. J Neurol Sci. 2017. PMID: 29246616 Review.
NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable tr …
NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA rema …
Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H, Kaczyński Ł, Górecka M, Rolka M, Wójcik R, Zięba P, Kaczor M. Bartosik-Psujek H, et al. Mult Scler Relat Disord. 2021 Apr;49:102769. doi: 10.1016/j.msard.2021.102769. Epub 2021 Jan 16. Mult Scler Relat Disord. 2021. PMID: 33516133
CONCLUSIONS: Cladribine in the form of tablets was significantly more effective in achieving NEDA-3 than DMF and TERI, but there was no significant difference vs FTY. Cladribine tablets was more effective than all oral comparators considering the MRI NEDA. For clini …
CONCLUSIONS: Cladribine in the form of tablets was significantly more effective in achieving NEDA-3 than DMF and TERI, but there was …
1,178 results